SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 397 filers reported holding SAREPTA THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 1.49 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $14,045,076 | -45.6% | 122,643 | -34.5% | 0.24% | -50.0% |
| Q1 2023 | $25,811,148 | -50.3% | 187,268 | -73.1% | 0.47% | -38.4% |
| Q1 2021 | $51,959,000 | -67.3% | 697,156 | -25.2% | 0.77% | -68.4% |
| Q4 2020 | $158,813,000 | +21.4% | 931,512 | 0.0% | 2.44% | -4.9% |
| Q3 2020 | $130,812,000 | -18.1% | 931,512 | -6.5% | 2.56% | -26.2% |
| Q2 2020 | $159,699,000 | +63.9% | 996,000 | 0.0% | 3.47% | +10.0% |
| Q1 2020 | $97,429,000 | -24.2% | 996,000 | 0.0% | 3.16% | -12.9% |
| Q4 2019 | $128,524,000 | +40.0% | 996,000 | -18.3% | 3.62% | +19.3% |
| Q3 2019 | $91,815,000 | -46.2% | 1,219,000 | +8.5% | 3.03% | -41.5% |
| Q2 2019 | $170,640,000 | +69.4% | 1,123,000 | +32.9% | 5.19% | +49.7% |
| Q1 2019 | $100,736,000 | +9.2% | 845,168 | 0.0% | 3.47% | -15.1% |
| Q4 2018 | $92,233,000 | -7.9% | 845,168 | +36.3% | 4.08% | +11.0% |
| Q3 2018 | $100,136,000 | +102.0% | 620,000 | +65.3% | 3.68% | +78.8% |
| Q2 2018 | $49,568,000 | +196.0% | 375,000 | +65.9% | 2.06% | +162.4% |
| Q1 2018 | $16,744,000 | +86.9% | 226,000 | +40.4% | 0.78% | +67.9% |
| Q4 2017 | $8,958,000 | +22.7% | 161,000 | 0.0% | 0.47% | +12.8% |
| Q3 2017 | $7,303,000 | +12.6% | 161,000 | -51.5% | 0.41% | +14.4% |
| Q1 2016 | $6,486,000 | -49.4% | 332,300 | 0.0% | 0.36% | -43.5% |
| Q4 2015 | $12,820,000 | +22.3% | 332,300 | +1.8% | 0.64% | +5.3% |
| Q3 2015 | $10,481,000 | +32.9% | 326,400 | +26.0% | 0.61% | +42.6% |
| Q2 2015 | $7,884,000 | +129.1% | 259,100 | 0.0% | 0.43% | +64.9% |
| Q1 2015 | $3,441,000 | -8.2% | 259,100 | 0.0% | 0.26% | -36.7% |
| Q4 2014 | $3,749,000 | -31.4% | 259,100 | 0.0% | 0.41% | -46.4% |
| Q3 2014 | $5,467,000 | -29.2% | 259,100 | 0.0% | 0.76% | -27.3% |
| Q2 2014 | $7,719,000 | +24.0% | 259,100 | 0.0% | 1.05% | +8.6% |
| Q1 2014 | $6,226,000 | +115.6% | 259,100 | +82.7% | 0.97% | +8.7% |
| Q4 2013 | $2,888,000 | – | 141,800 | – | 0.89% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Asymmetry Capital Management, L.P. | 105,066 | $4,766,000 | 5.53% |
| Camber Capital Management LP | 1,400,000 | $63,504,000 | 4.02% |
| SPHERA FUNDS MANAGEMENT LTD. | 384,997 | $17,463,000 | 2.49% |
| GREAT POINT PARTNERS LLC | 250,000 | $11,340,000 | 2.21% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 121,000 | $5,489,000 | 2.14% |
| Elk Creek Partners, LLC | 716,516 | $32,501,000 | 2.05% |
| HealthCor Management, L.P. | 1,202,770 | $54,558,000 | 1.83% |
| Tourbillon Capital Partners, L.P. | 1,531,331 | $69,461,000 | 1.68% |
| EMERALD ADVISERS, LLC | 893,484 | $40,528,000 | 1.65% |
| Tourbillon Capital Partners, L.P. | 1,470,400 | $66,697,000 | 1.62% |